Effectiveness and Safety of Autologous Bone Marrow Stromal Cells Transplantation After Ischemic Stroke: A Meta-Analysis

Wenyling Cao

Pan Li

Corresponding Author: Pan Li, e-mail: lipan_1983@126.com

Source of support: Self financing

Background: Autologous bone marrow stromal cells (BM-SCs) transplantation might be a potential therapy for stroke. Although a series of clinical trials were performed to assess the effectiveness and safety of BM-SCs transplantation after ischemic stroke, the results are still conflicting. This study aimed to pool previous controlled trials to assess the effectiveness of BM-SCs-based cell therapy after ischemic stroke.

Material/Methods: Relevant studies were searched among online databases. Barthel index (BI) or modified Barthel index (mBI), National Institutes of Health Stroke Scale (NIHSS), and Rankin Score (mRS) were used to assess therapeutic effects. The frequencies of adverse events were extracted for assessing safety of stem cell therapy. Data analysis was performed by using Review Manager 5.3.

Results: Patients who received cell therapy had significantly lower NIHSS score (–1.85) than the controls. In addition, there might be some benefits in daily activity measured by mBI, but this meta-analysis failed to demonstrate significant benefits of BM-SCs-based cell therapy in increasing the proportion of mRS ≤2 patients. We did not find any severe adverse events associated with BM-SCs-based cell therapy.

Conclusions: Although BM-MNCs/MSCs transplantation might generate some benefits in lowering the grade of impairment caused by ischemic stroke, large RCTs are required to further confirm the effectiveness of BM-MSCs/MNCs-based cell therapy and to optimize the conditions required for best therapeutic effects.

MeSH Keywords: Mesenchymal Stromal Cells • Meta-Analysis • Stroke

Full-text PDF: http://www.medscimonit.com/abstract/index/idArt/895081
Background

Stroke accounts for approximately 11% of all deaths worldwide and is the most common cause of adult-acquired disability [1,2]. Among all stroke cases, ischemic stroke and intracerebral hemorrhage (ICH) account for about 80-85% and 15–20%, respectively. Intravenous thrombolysis by using tissue plasminogen activator (tPA) is the only approved treatment for acute ischemic stroke. However, tPA has very narrow time window (within 4.5 h after onset) of application. Therefore, only a minority of patients (2% to 4%) can receive timely therapy [3]. It is necessary to develop more effective therapeutic practices.

Cell therapy might be a promising strategy for stroke. Bone marrow-derived mononuclear cells (BM-MNCs) and mesenchymal stem cells (BM-MSCs) both are bone marrow stromal cells (BM-SCs) and are most frequently used in preclinical and clinical neurorestorative studies in stroke. BM-MNCs/MSCs have self-renewal capacity and pluripotency to differentiate into several mesenchymal cellular lineages, including osteoblasts, chondroblasts, adipocytes, myocytes, and fibroblasts [4,5]. They can also differentiate into non-mesenchymal lineages, including neurons and glial cells [6]. Preclinical studies observed that BM-MNCs/MSCs transplanted either intracranially or intravascularly could migrate to damaged brain tissue and exert a neuroprotection effect by inhibiting apoptosis, decreasing peri-infarct infarction, and promoting angiogenesis [7–9]. This mechanism makes BM-MNCs/MSCs therapy a potential therapeutic strategy for stroke. Therefore, during the past decade, a series of clinical trials was performed to assess the effectiveness and safety of BM-SCs transplantation after stroke. However, the results are still conflicting. Due to the small number of patients recruited in individual trials, the statistical power of the conclusions is weak. One recent single-arm meta-analysis showed this cell therapy could effectively improve National Institutes of Health Stroke Scale (NIHSS) scores, modified Barthel index (mBI) or modified Rankin score (mRS) [10]. However, without comparison with a control group, there might have observational bias. Therefore, this study aimed to pool previous controlled trials to assess the effectiveness of BM-SCs-based cell therapy after ischemic stroke.

Material and Methods

Study search and selection

This study generally followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Study selection and data extraction were performed by 2 authors independently. Relevant studies published from 1 Jan 2000 to 1 Sept 2014 were searched among PubMed, Medline, Embase, and the Cochrane database. We only included randomized or non-randomized controlled trials that assessed effectiveness of BM-MNCs/MSCs-based cell therapy in either ischemic stroke patients. Studies with unclear or without extractable data were excluded.

Data extraction

The basic data extracted from original studies included: family name of the first author, year of publication, type of stroke, study design, number of patients, mean age, type of cell used, route of cell delivery, number of cells injected, time interval from stroke to therapy, follow-up, baseline NIHSS score, and outcome indicator measured. To assess the effectiveness of cell therapy, the outcome indicators used to assess therapeutic effectiveness include modified Rankin Score (mRS), Barthel index (BI) or modified Barthel index (mBI), and National Institutes of Health Stroke Scale (NIHSS). The frequencies of adverse events were extracted for assessing safety of stem cell therapy.

Statistical analysis

Original data were pooled and analyzed by using Review Manager 5.3 (the Cochrane Collaboration). The risk ratio (RR) and corresponding 95% confidence intervals (CI) of mRS ≤2 (cell therapy vs. control) were estimated. For the discontinuous data, including BI or mBI and NIHSS score, weighted mean difference (WMD) and corresponding 95% (CI) was estimated. The chi-square based Q test and I² value were used to assess between-study heterogeneity, which also determines the methods used for making estimation. The random-effects model (DerSimonian and Laird method) was used when p <0.1 in Q test or I² >50%, which indicates significant heterogeneity. Otherwise, the fixed-effects model based on Mantel-Haenszel method was applied. If unacceptable high heterogeneity was observed, the sources of heterogeneity were further explored. If significant clinical heterogeneity existed, subgroup analysis was performed. p<0.5 in Z test was considered statistically significant in the pooled results.

Results

Based on searching and screening with the preset criteria, 5 trials [11–15] were finally included in this meta-analysis. The general searching and screening process is summarized in Figure 1. The basic features of the 5 trials are given in Table 1. The 5 trials involved a total of 228 patients, among which 104 were in the cell therapy group and 124 were in the control group. Two studies used BM-MSCs [11,12] and 3 studies used BM-MNCs [13–15]. Four studies transplanted cells through IV injection [11–13,15] and 1 used IA injection [14]. The number of cells injected ranged from 5×10⁴ to 2.6×10⁶. The time interval from stroke to cell therapy varied from several days...
to several months after stroke. Four trials reported outcome with 6-month follow-up, while 1 study reported 5-year outcome. Generally, modified Rankin score (mRS), Barthel index (BI), modified BI (mBI), and National Institutes of Health Stroke Scale (NIHSS) scores are the 3 indicators most used to assess clinical outcomes of cell therapy.

The effect of BM-MSCs on BI or mBI score

Two studies reported BI and 2 studies reported mBI at the end of follow-up. Generally, although the cell therapy group had slightly higher BI or mBI score, the mean difference was not significant between cell therapy and control group (WMD: 2.50, 95%CI: –4.69 to 9.68, p=0.50, I²=46%) (Figure 2). Subgroup analysis was performed by stratifying BI and mBI. Subgroup using mBI as the indicator of daily activities of living reported significantly higher mBI score in the cell therapy group than in the controls (WMD: 7.44, 95%CI: 1.82 to 13.06, P=0.009, I²=0%) (Figure 2), but no significant difference was observed in the BI subgroup (WMD: –3.24, 95%CI: –12.14 to 5.65, P=0.47, I²=0%) (Figure 2).

The effect of BM-MSCs on NIHSS score

Two studies reported NIHSS at the end of follow-up. Generally, the mean difference of NIHSS score was significant lower in the cell therapy group than in the control group (WMD: –1.85, 95%CI: –2.77 to –0.93, P<0.0001, I²=24%) (Figure 3).

Table 1. The key characteristics of trials included.

| Study       | Type of stroke               | Baseline NIHSS score | Type of cells          | Route of Delivery | No. cells injected | Time interval from stroke to therapy | Follow-up | Outcome measured |
|-------------|------------------------------|----------------------|------------------------|-------------------|-------------------|-------------------------------------|-----------|------------------|
| Lee 2010    | MCA ischemic stroke          | ≥7                   | Autologous BM-MSCs     | IV                | 5×10⁷ (2 times with 2 weeks interval) | 19 to 37 days | 5 years        | mRS              |
| Bhasin 2012 | chronic ischemic stroke      | 4–15                 | Autologous BM-MNCs     | IV                | 5.5×10⁷           | Mean 9.3 months                      | 6 months  | mBI              |
| Moniche 2012| MCA ischemic stroke          | ≥8                   | Autologous BM-MNCs     | IA                | Mean 1.6×10⁸      | 5 to 9 days                          | 6 months  | mRS, BI, NIHSS   |
| Prasad 2014 | subacute ischemic stroke     | Median 12            | Autologous BM-MNCs     | IV                | Mean 2.6×10⁸      | Median of 18.5 days                  | 6 months  | mRS, BI, NIHSS   |
| Bhasin 2011 | MCA ischemic or hemorrhagic stroke | 4–15             | Autologous BM-MSCs     | IV                | 5–6×10⁷          | Mean 9.3 months                      | 6 months  | mBI              |

RCT – randomized controlled trial; NRCT – non-randomized controlled trial; BM-MNCs – bone marrow mononuclear cells; N.A. – not available; MCA – middle cerebral artery; IC – intracerebral; IA – intra-arterial; IV – intravenous; mRS – modified Rankin Score; BI – Barthel index; mBI – modified BI; NIHSS – National Institutes of Health Stroke Scale.
The effect of BM-MSCs on mRS

Three studies reported the change in mRS at the end of follow-up. Due to the non-randomized design of some studies, we only compared the proportion of patients with mRS ≤2 before and after cell therapy in the experimental arm. The meta-analysis did not find significant change in the proportion of patients in the mRS ≤2 group before and after cell therapy (13/86 vs. 15/86) (RR: 1.81, 95% CI: 0.37 to 8.95, p=0.47) (Figure 4).

Safety assessment of BM-MSCs transplantation

Infection, recurrence of stroke, and death were used to assess the safety of BM-MSCs transplantation. Our meta-analysis did not find any difference in these 3 indicators between the cell therapy and control group (Figure 5).
In animal models, transplantation of BM-MNCs or MSCs could reduce inflammation, decrease the infarct size in the brain, and improve neurological function in several models of stroke through multiple mechanisms [16–18]. A recent meta-analysis based on 46 preclinical animal studies also confirmed these effects [19]. Previous preclinical studies observed that although BM-MSCs and BM-MNCs could transdifferentiate into neuronal-like in vitro, they did not have basic neuronal functional properties [20,21]; this transdifferentiation seldom happens in vivo [16]. In fact, a study based on animal models showed that only a very small proportion (about 0.02%) of the intravenously delivered BM-MNCs migrate to the ischemic area of the brain, while most of the transplanted cells develop a macrophage/microglial phenotype [22]. Therefore, transdifferentiation is not the key mechanism mediating the possible therapeutic effects. Generally, the transplanted cells have a stimulating effect on release of cytokines and neurotrophic factors, including brain-derived neurotrophic factor (BDNF), basic fibroblast growth factor (bFGF), nerve growth factor, vascular endothelial growth factor (VEGF), insulin-like growth factor-1, hepatocyte growth factor (HGF), and stem cell factor [9,22]. These factors can induce angiogenesis, reduce neuronal apoptosis, enhance axonal regeneration, rebuild synapses and dendrites, and promote differentiation of endogenous neural stem and progenitor cells [9,22]. These effects do not necessarily require the presence of transplanted cells at the injury site in the brain. Therefore, the paracrine effects of transplanted cells might be fundamental to positive clinical outcomes. However, in clinical trials, data on the exact effects of BM-MNCs/MSCs-based cell therapy after stroke are still conflicting.

This study, based on 5 double-arms trials, demonstrated that BM-derived stromal cells might have some benefits in lowering the grade of impairment caused by ischemic stroke. Patients who received cell therapy had significantly lower NIHSS score controls. The lowered NIHSS score was a powerful indicator of excellent outcome after stroke. In fact, a 1-point increase of NIHSS score decreases the likelihood of an excellent outcome by 17% [23]. In addition, there might be some benefits in activities of daily living as measured by mBI. However, the studies involved a limited number of patients and were conducted by a same research team, so the statistical power of the finding might be weak. Clinical trials usually define favorable outcome of stroke as mRS grade ≤2 [24]. However, this meta-analysis failed to demonstrate significant benefits of BM-MSCs/MNCs-based cell therapy in increasing the proportion of mRS ≤2 patients. Due to the small number of trials and patients included, this finding is also inconclusive. This study did...
not find any severe adverse events associated with cell therapy, suggesting it is a relatively safe intervention.

This study also has several limitations. Firstly, the number of trials and the number of patients recruited in each trial were small. In addition, different trials reported different clinical outcomes, which makes it hard to use the same scale to summarize the results. These limitations significantly weaken the statistical power of the findings. Secondly, to develop an effective cell therapy strategy, several factors, including eligibility criteria of the patients, timing, and route and dose of cell transplantation, should be considered in clinical practice. However, based on the available evidence, these factors still need to be optimized. These factors also might have contributed to the heterogeneity of this study. Patients with moderate, but not mild or severe, stroke might be more suitable for cell therapy, since patients with mild strokes generally have uniformly good outcome and patients with severe stroke are less likely to respond to the intervention and thus are unlikely to have good outcome. The 5 trials recruited patients with basic NIHSS scores ranging from 4 to 20, which means minor, moderate, and moderate-to-severe patients were all recruited. Therefore, their different responses to cell therapy might generate observational bias.

## Conclusions

Although BM-MNCs/MSCs transplantation might generate some benefits in lowering the grade of impairment caused by ischemic stroke, large RCTs are required to further confirm the effectiveness of BM-MSCs/MNCs-based cell therapy and to optimize the conditions required for best therapeutic effects.

## References:

1. Norrving B, Kissela B: The global burden of stroke and need for a continuum of care. Neurology, 2013; 80(3 Suppl.2): 55–12
2. Lozano R, Naghavi M, Foreman K et al: Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, 2012; 380(9843): 2095–2098
3. Molina CA: Reperfusion therapies for acute ischemic stroke: current pharmacological and mechanical approaches. Stroke, 2011; 42(1 Suppl.): S16–19
4. Law S, Chaudhari S: Mesenchymal stem cell and regenerative medicine: regeneration versus immunomodulatory challenges. Am J Stem Cells, 2013; 2(1): 22–38
5. Xu SY, Pan SY: The failure of animal models of neuroprotection in acute ischemic stroke to translate to clinical efficacy. Med Sci Monit Basic Res, 2013; 19: 37–45
6. Brazeleton TR, Rossi FM, Keshet GJ, Blau HM: From marrow to brain: expression of neuronal phenotypes in adult mice. Science, 2000; 290(5497): 1775–79
7. Goparajpillai P, Pal R, Mamidi MK et al: Stem cells in stroke repair: current success and future prospects. CNS Neurol Disord Drug Targets, 2011; 10(6): 741–56
8. Giraldi-Guimardes A, Rezende-Lima M, Bruno FP, Mendez-Otero R: Treatment of bone marrow mononuclear cells induces functional recovery and decreases neurodegeneration after sensorimotor cortical ischemia in rats. Brain Res, 2009; 1268: 108–20
9. Han W, Li F, Zhu L et al: Update on therapeutic mechanism for bone marrow stromal cells in ischemic stroke. J Mol Neurosci, 2014; 52(2): 177–85
10. Jeong H, Yim HW, Cho YS et al: Efficacy and safety of stem cell therapies for patients with stroke: a systematic review and single arm meta-analysis. Int J Stem Cells, 2014; 7(2): 63–69
11. Lee JS, Hong JM, Moon GI et al: A long-term follow-up study of intravenous autologous mesenchymal stem cell transplantation in patients with ischemic stroke. Stem Cells, 2010; 28(6): 1099–106
12. Bhasin A, Srivastava MV, Kumaran SS et al: Autologous mesenchymal stem cells in chronic stroke. Cerebrovascular Dis Extra, 2011; 1(1): 93–104
13. Bhasin A, Srivastava M, Bhatia R et al: Autologous intravenous mononuclear stem cell therapy in chronic ischemic stroke. J Stem Cells Regen Med, 2012; 8(3): 181–89
14. Moniche F, Gonzalez A, Gonzalez-Marcos JR et al: Intra-arterial bone marrow mononuclear cells in ischemic stroke: a pilot clinical trial. Stroke, 2012; 43(8): 2242–44
15. Prasad K, Sharma A, Garg A et al: Intravenous autologous bone marrow mononuclear stem cell therapy for ischemic stroke: a multicentric, randomized trial. Stroke, 2014; 45(12): 3618–24
16. Schwarting S, Litwak S, Hao W et al: Hematopoietic stem cells reduce post-ischemic inflammation and ameliorate ischemic brain injury. Stroke, 2008; 39(10): 2867–75
17. Kawabori M, Kuroda S, Sugiyama T et al: Intracerebral, but not intravenous, transplantation of bone marrow stromal cells enhances functional recovery in rat cerebral infarct: an optical imaging study. Neuropathology, 2012; 32(3): 217–26
18. Wu J, Sun Z, Sun HS et al: Intravenously administered bone marrow cells migrate to damaged brain tissue and improve neural function in ischemic rats. Cell Transplant, 2008; 16(10): 993–1005
19. Vu Q, Xie K, Eckert M et al: Meta-analysis of preclinical studies of mesenchymal stem cells in ischemic stroke. Neurology, 2014; 82(14): 1277–86
20. Barnabe GF, Schwindt TT, Cacagnotto ME et al: Cellically-induced RAT mesenchymal stem cells adopt molecular properties of neuronal-like cells but do not have basic neuronal functional properties. PLoS One, 2009; 4(4): e5222
21. Roybon L, Ma Z, Azelyn F et al: Failure of transdifferentiation of adult hematopoietic stem cells into neurons. Stem Cells, 2006; 24(6): 1594–604
22. Rosado-de-Castro PM, Pimentel-Coelho PM, da Fonseca LM et al: The rise in cell therapy trials for stroke: review of published and registered studies. Stem Cells Dev, 2013; 22(15): 2095–111
23. Adams HP Jr, Davis PH, Leira EC et al: Baseline NIH Stroke Scale strongly predicts outcome after stroke: A report of the Trial of Org 10172 in Acute Stroke Treatment (TOAST). Neurology, 1999; 53(1): 126–31
24. Grotta J: Lubeluzole treatment of acute ischemic stroke. The US and Canadian Lubeluzole Ischemic Stroke Study Group. Stroke, 1997; 28(12): 2338–46